Stockreport

AptarGroup outlines 2026 margin improvement and targets 7%–11% long-term pharma core sales growth amid emergency medicine headwinds [Seeking Alpha]

AptarGroup, Inc.  (ATR) 
Last aptargroup, inc. earnings: 4/30 05:04 pm Check Earnings Report
US:NYSE Investor Relations: investors.aptar.com
PDF CEO Stephan Tanda emphasized "very strong top line performance" for Q4, with reported sales growing 14% to $963 million and core sales up 5%. Tanda noted, "Adjusted EBI [Read more]